Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Patients with mantle cell lymphoma require treatment options following BTK inhibition, as evidenced by the 14.6 months median OS rate from initiation of BTK inhibitor in the recently published SCHOLAR-2 analysis [[11]]. Nine patients were refractory to prior therapy, 9 had previously received a BTK inhibitor (BTKi) including 7 who were refractory to BTKi and there were 3 who had progressive lymphoma following chimeric antigen receptor T-cell (CAR-T) therapy. Novel agents such as the Bruton's tyrosine kinase (BTK) inhibitors have improved outcomes for patients with mantle cell lymphoma (MCL) and continue to change treatment paradigms [[1]]. [Extracted from the article]